STLN · Starling Oncology, Inc. · Webcasts, Transcripts & Audio
$3.35
+0.15 (+4.69%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$326.37M
Shares
101.99M
Volume · Nov 18
4.68M
Avg daily vol (3M)
2.45M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Starling Oncology, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Starling Oncology, Inc. (STLN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call
Revenue
$169.77M
▲ 24.3% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-08
Starling Oncology, Inc. (STLN) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Confident tone
Capitated contract growth and geographic expansion
Guidance and outlook
Specialty pharmacy business
Revenue
$161.28M
▲ 34.6% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Starling Oncology, Inc. (STLN) Q1 2026 Earnings Call Transcript
Confident tone
Florida market expansion and profitability
Revenue scale and capitated lives growth
Specialty pharmacy growth
Revenue
$147.44M
▲ 41.2% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Starling Oncology, Inc. (STLN) Q4 2025 Earnings Call Transcript
Confident tone
Capitated/delegated growth and Elevance partnership
Florida onboarding and 2027 MA rate environment
Payer partnerships expansion (Florida, Humana, CarePlus)
Revenue
$141.96M*
▲ 41.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Starling Oncology, Inc. (STLN) Q3 2025 Earnings Call Transcript
Confident tone
Macro and policy environment
Pharmacy business expansion
AI initiatives and operational efficiency
Revenue
$136.56M
▲ 36.7% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Starling Oncology, Inc. (STLN) Q2 2025 Earnings Call Transcript
Confident tone
Pharmacy business growth
Florida market expansion
Fully delegated model explanation
Revenue
$119.80M
▲ 21.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Starling Oncology, Inc. (STLN) Q1 2025 Earnings Call Transcript
Confident tone
Capitation contract wins
Fee-for-service recovery
Path to profitability and cash flow
Revenue
$104.41M
▲ 10.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-24
Starling Oncology, Inc. (STLN) Q4 2024 Earnings Call
Revenue
$100.27M*
▲ 16.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Starling Oncology, Inc. (STLN) Q3 2024 Earnings Call Transcript
Positive tone
Liquidity and balance sheet
Cost optimization and SG&A reduction
Capitated contract growth
Revenue
$99.90M
▲ 21.8% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Starling Oncology, Inc. (STLN) Q2 2024 Earnings Call Transcript
Positive tone
DIR fee impact and drug margin compression
Capitation contracts and value-based care growth
Profitability path and guidance
Revenue
$98.58M
▲ 22.9% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Starling Oncology, Inc. (STLN) Q1 2024 Earnings Call Transcript
Positive tone
Capitation and value-based contracts
Strategic priorities and market expansion
Cash burn and liquidity
Revenue
$94.67M
▲ 24.2% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Starling Oncology, Inc. (STLN) Q4 2023 Earnings Call Transcript
Confident tone
Florida Market Expansion
DIR Fees and Drug Margin Pressure
Value-Based Contracts and Risk Expansion
Revenue
$85.79M*
▲ 20.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Starling Oncology, Inc. (STLN) Q3 2023 Earnings Call Transcript
Revenue
$82.03M
▲ 26.3% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Starling Oncology, Inc. (STLN) Q2 2023 Earnings Call Transcript
Revenue
$80.22M
▲ 31.7% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Starling Oncology, Inc. (STLN) Q1 2023 Earnings Call Transcript
Revenue
$76.19M
▲ 38.1% YoY Diluted EPS
$-0.33
▼ 257.1% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Starling Oncology, Inc. (STLN) Q4 2022 Earnings Call Transcript
Revenue
$71.42M*
▲ 36.6% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-15
Starling Oncology, Inc. (STLN) Q3 2022 Earnings Call Transcript
Revenue
$64.98M
▲ 24.3% YoY Diluted EPS
$-0.17
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-16
Starling Oncology, Inc. (STLN) Q2 2022 Earnings Call Transcript
Revenue
$60.92M
▲ 22.2% YoY Diluted EPS
$-0.06
▼ 220% YoY
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Starling Oncology, Inc. (STLN) Q1 2022 Earnings Call Transcript
Revenue
$55.16M
▲ 13.5% YoY Diluted EPS
$0.21
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-11
Starling Oncology, Inc. (STLN) Q4 2021 Earnings Call Transcript
Revenue
$52.30M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Showing 1–21 of 21 webcasts
Key facts
CIK
1799191
CUSIP
68236X100
13F (30d)
140 filings
127 filers
Visit website
Investor relations